Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - risedronate sodium; calcium carbonate; colecalciferol; cholecalciferol -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - risedronate sodium; calcium carbonate -

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - ciclopirox 8% - nail lacquer - 8 % - active: ciclopirox 8% excipient: butyl ester of pvm/ma copolymer ethyl acetate isopropyl alcohol nitrogen

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - ciclopirox olamine 1%{relative} - topical cream - 1% w/w - active: ciclopirox olamine 1%{relative}

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - ciclopirox olamine 1%{relative} - topical solution - 1% w/v - active: ciclopirox olamine 1%{relative}

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - sodium cromoglicate 5mg equivalent to 3.5211% w/w;  ;   - aerosol inhaler, metered dose - 5 mg/dose - active: sodium cromoglicate 5mg equivalent to 3.5211% w/w     excipient: apaflurane macrogol 600 povidone - intal forte 5 mg cfc-free is indicated for the preventive treatment of bronchial asthma (which may be due to allergy, exercise, cold air or chemical irritants) in adults and children.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - nedocromil sodium 1.4085%{relative} (2 mg/dose);   - aerosol inhaler, metered dose - 2 mg/dose - active: nedocromil sodium 1.4085%{relative} (2 mg/dose)   excipient: apaflurane macrogol 600 menthol povidone - tilade cfc-free is indicated in the treatment of bronchial asthma (whether extrinsic or intrinsic in nature, and including asthmatic bronchitis, late onset asthma, exercise induced asthma, and bronchospasm provoked by a variety of stimuli such as cold air, inhaled allergens, atmospheric pollutants and other irritants). tilade cfc-free is intended for regular prophylactic treatment and not for symptomatic relief. in the management of asthma, tilade cfc-free improves pulmonary function, reduces the frequency and severity of attacks and reduces bronchospasm, cough and bronchial hyper-responsiveness. in patients already receiving treatment for their asthma, tilade cfc-free can be given in addition to all existing therapies and will in many cases provide added therapeutic benefit. having established this benefit of tilade cfc-free, it may be possible to gradually reduce or eliminate concomitant therapy.

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - insulin glulisine - injection, solution - 3.49 mg (100 units) - insulin glulisine 3.49 mg (100 units)

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - insulin glargine - injection, solution - 100 iu/ml - insulin glargine 100 iu/ml

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - lixisenatide - injection, solution - 50mcg/ml - lixisenatide 50mcg/ml